Dabrafenib Plus Trametinib for BRAF V600E-Mutant Non-small Cell Lung Cancer: A Patient Case Report

Dabrafenib plus trametinib is US Food and Drug Administration approved combination therapy for use in patients with BRAF V600E-mutant non-small cell lung cancer, but information on use outside of clinical trials is limited. We report the case of a 70-year-old Asian woman (never smoker) who was diagn...

Descripción completa

Detalles Bibliográficos
Autor principal: Pan, Janet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765470/
https://www.ncbi.nlm.nih.gov/pubmed/31250402
http://dx.doi.org/10.1007/s40261-019-00823-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765470/
https://www.ncbi.nlm.nih.gov/pubmed/31250402
http://dx.doi.org/10.1007/s40261-019-00823-3

Ejemplares similares